A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Lumasiran (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 08 Jan 2019 Planned number of patients changed from 24 to 20.
- 25 Oct 2018 According to the Alnylam Pharmaceuticals media release, new results were reported at the American Society of Nephrology (ASN) 2018 Annual Meeting.
- 08 Jun 2018 According to the Alnylam Pharmaceuticals media release, company expects to present data from this study in late 2018.